TruTalk

www.truveris.com

0 notes &

Truveris Launches RxDash, a Game-Changer that Allows Instant Price and Plan Design Modeling for Pharmacy Benefits Changes

NEW YORK, Aug. 25, 2014 /PRNewswire/ — Truveris, a premier pharmacy benefit pricing and analytics company, today announced the launch of RxDashSM, an enterprise platform for pharmacy plan repricing, modeling and reporting. A cutting-edge Software-as-a-Service (SaaS) solution, RxDash enables pharmacy benefit managers (PBMs), health insurers, consulting companies and plan administrators to view in real time the price impact of proposed benefits and price changes.

RxDash helps better meet today’s customer expectations by cutting out the traditional multi-week lag-time for insight into the plan design, pricing and member impact of potential modifications. For PBMs, health insurers and large consulting practices, RxDash calculates in real time how proposed benefit changes increase or decrease costs, illustrates how plan changes affect employees, and helps visualize the impact of step therapy and prior authorizations on plan costs. The robust reporting platform provides ad-hoc and recurring reporting to end clients.

"RxDash eliminates the manual processes that often can take four weeks to complete before employers can understand the impact of a plan design change," said Bryan Birch, CEO of Truveris. "RxDash immediately calculates the impact of changes so PBMs, brokers, consultants and administrators can make better decisions and ultimately serve their customers more efficiently and effectively. The pricing and reporting platforms are unlike anything available in the market today."

RxDash is the latest enterprise addition to the Truveris portfolio of tools designed to deliver unprecedented transparency, analytics and reporting to the pharmacy benefit industry, bringing clients new autonomy in making important benefit cost, design and procurement decisions. The fast-growing company’s cloud-based platform currently analyzes nearly 10% of the prescriptions in the U.S., giving Truveris unique insights into the issues and challenges of the $300 billion prescription drug industry in the U.S.

To find out more about this groundbreaking new cloud solution or to view Truveris’ other pharmacy industry products, please visit: www.truveris.com

About Truveris 
Founded in 2009, Truveris enables efficiency, transparency and cost management across the pharmacy benefit process through cloud based, SaaS solutions for PBMs, health insurers, benefit consultants and self-insured companies. Based in New York City, Truveris is funded by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. For more information, visit truveris.com.

                                                 ###

Full Press Release: http://on.mktw.net/1vSaIau

0 notes &

TruNews: August 2014

Which Drugs are CVS Caremark and Express Scripts Restricting?

CVS Caremark has excluded 95 medicines in 2015, as compared to 72 this year; while Express Scripts has excluded 66 medicines in 2015, up from 48 this year. Savings with these exclusions are expected to be $4.5 billion collectively for the PBMs. 

Link to Article: WSJ

Related Articles: Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boost

WellPoint Will Change Name to Anthem to Reach Consumers 

In order to align its company with the brand under which it sells the majority of coverage, WellPoint will change its name to Anthem Inc. WellPoint is the second-largest health insurance company in the U.S. and sells plans in 14 health exchanges, usually under its Anthem brand. 

Link to Article: Bloomberg

16% Of Large Employers Plan To Offer Low-Benefit ‘Skinny’ Plans Despite ACA: Survey

A new survey found that 16% of large employers plan to offer low-benefit health coverage that does not meet the ACA requirements for affordability and value. These “skinny plans” are allowed by ACA regulations; and may expand outside of industries that traditionally provide low-benefit coverage, like restaurant chains and hotels.

Link to Article: Kaiser Health News

AstraZeneca to Pay Almirall Up to $2.1 Billion for Respiratory Drugs 

AstraZeneca agreed to pay up to $2.1 billion for a suite of respiratory drugs from Almirall, a Spanish pharmaceutical manufacturer. AZ will own the development and commercialization rights to Almirall’s current respiratory business, including a treatment for chronic obstructive pulmonary disease, Eklira.

  Link to Article: NYT DealBook

Big Pharma is using its venture cash to outsource early R&D to biotech

Pharmaceutical companies are increasingly investing in biotech companies to outsource a portion of their own R&D work, bringing the corporate venture funding for biotech companies back up to 2008 levels. According to Silicon Valley Bank, this trend suggests there will be a rise in the number of M&A deals, with the largest deals likely to be worth more than $75 million upfront. 

Link to Article: FierceBiotech

Walgreen CEO: Leaving U.S. wasn’t in best interest of shareholders

In a $15.26 billion deal that keeps its corporate headquarters in the U.S., Walgreen has exercised its option to purchase the remaining 55% of Alliance Boots. Greg Wasson, Walgreen President and CEO, said that a corporate inversion was not in the best interest of shareholders. 

Link to Article: Chicago Tribune

Related Article: Walgreens and Alliance Boots to Combine; No Inversion For You!

Skeptical U.K. watchdogs decide to back Gilead’s Hep C star Sovaldi

While the U.S. and Europe payers have been skeptical about paying for Gilead’s Sovaldi, the U.K.’s National Institute for Health and Care Excellence (NICE) may end up approving Sovaldi. NICE criticized Gilead’s cost analysis and data in patients with particular subtypes of HCV.

Link to Article: FiercePharma

Related Opinion Article: UK Says Sovaldi is Worth It. We Should Listen.

                                                 ###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 646.365.3125
www.truveris.com

0 notes &

TruNews: July 2014

Prescription Auditing Service Truveris Raises $12.75 Million

Truveris has raised $12.75 million in a new round of funding led by Canaan Partners. Reviewing 300 million claims annually, Truveris software reviews bills received by payers for prescription fulfillment. 

Link to Article: TechCrunch

Related Articles: PR Newswire | Crain’s New York

   

Express Scripts Ends Coverage for 1,000 Compound Drug
Ingredients

Express Scripts is blocking coverage for about 1,000 active ingredients that are used by compounding pharmacists to create numerous topical treatments. Insurance does not cover many compounded medications, such as those used for cosmetic purposes. 

Link to Article: WSJ

Related Articles: Drugs Not Covered by Express Scrpts and CVS Caremark |
Health Insurers Pressing Down on Drug Prices

    

Drugmakers Shire, AbbVie near $53B merger

Shire, the pharmaceutical manufacturer of attention deficit hyperactivity disorder drugs Vyvanse and Adderall XR,  reported that its board anticipates recommending the $53 billion improved offer from Chicago-based AbbVie. AbbVie has offered £53.20 per share for Shire, and would grant Shire shareholders about 25% of the combined new AbbVie. 

Link to Article: USA Today

Related Articles: Abbott Labs to Sell Generic Assets to Mylan |
Roche Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

    
Academic Witnesses Criticize PBM Compensation Disclosure
Mandates

The ERISA Advisory Council is considering this year whether to require PBMs to make disclosures on compensation and fees to employee health plan sponsors. More transparency is seen to improve vendor competition and plan sponsor administration of benefits. 

 Link to Article: RxObserver.com

Humana May Explore Co-Sourcing Deal, But Do Viable PBM
Partners Remain?

While there have been rumors that Humana Inc. might sell its PBM division to Express Scripts, CVS Caremark, or Catamaran for up to $7 billion, Humana President and CEO Bruce Broussard recently suggested that outsourcing might be on the table. Such an arrangement could create more efficiency while maintaining the advantages of an in-house PBM. 

Link to Article: AIS Health

  

Senate Committee is Investigating Pricing of Hepatitis C Drug

The U.S. Senate Finance Committee is investigating Gilead Sciences Inc.’s pricing of the Hep C drug Sovaldi, which costs about $84,000 per patient 12-week regimen. Senators Grassley and Wyden are scrutinizing the original Pharmasset Inc. pricing of the drug at $36,000 before Gilead acquired Pharmasset in 2011.

Link to Article: WSJ

     

Generic Drug Pricing Bill is Bipartisan Effort

Colorado House Bill 1213 aims to bring greater transparency to generic drug pricing by requiring PBMs to disclose the basis for determining MAC pricing in their contracts with pharmacies and to update pricing information every seven days. 

Link to Article: The Pueblo Chieftan

                                                  ###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 646.365.3125
www.truveris.com

0 notes &

Pharmacy Pricing & Benefits Analysis Platform Truveris Raised Another $12.75M

NEW YORK, June 27, 2014 /PR Newswire/ — Truveris, a leading platform for pharmacy pricing and benefits analysis, today announced it raised $12.75 million in a Series C Round financing.  Canaan Partners led the investment and was joined by existing investors New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. Truveris will use the funds to scale the firm’s sales and marketing teams and further product development.  

"Truveris is solving one of the most critical issues facing the health care industry today: reducing prescription costs and providing better access," said Canaan Partners general partner, Stephen Bloch, who will join Truveris’ board. "With a sophisticated and comprehensive solution, the company offers the best analytical tools on the market to change the existing cost structure. To date, they have already saved their 200 customers and 30 million members millions of dollars.

Founded in 2009, Truveris offers unions, self-insured companies, government entities, health insurers, benefit consultants, and pharmaceutical manufacturers unprecedented transparency into pharmaceutical benefit costs, design and procurement. Doubling revenue each year, Truveris’ cloud-based platform currently analyzes approximately 10% of the prescriptions in the U.S. 

"Truveris continues to advance the management and access of pharmacy benefits, which is a $300 billion industry in the U.S. alone," said Michael Miele, Area President NY Metro Region for the international insurance brokerage and risk management services company Arthur J. Gallagher. "We utilize the latest technology from Truveris to evaluate and monitor prescription costs, which enables us to provide the highest level of service to our clients. Their plan design modeling and reporting tools are unlike anything available in the market today."

Truveris’ SaaS solutions include TruGuard®, a platform that audits the costs of prescription claims, TruBid®, a pricing platform for large companies to compare pharmacy benefit offerings from leading pharmaceutical benefit management companies (PBMs), and RxChoiceSM, which provides similar services for the mid-to-small market. Additionally, the company recently launched TruReport® and RxDashSM, which provide pricing and reporting suites for PBMs, health insurers and large consulting practices.

"There is an enormous opportunity to optimize pharmacy benefits management and design," said Bryan Birch, CEO of Truveris. "The market has not substantially changed in the past decade and we’re thrilled to be partnering with Canaan Partners and our existing investors to implement much needed improvements. With this funding, we will further develop our product portfolio to assist additional stakeholders in the pharmaceutical market including manufacturers and retailers resulting in improved consumer access and costs."

About Truveris

Founded in 2009, Truveris makes software to drive efficiency, transparency and cost containment in the prescriptions claims process. Truveris helps payers of pharmacy benefits negotiate agreements with Prescription Benefit Managers (PBMs), validate claim payment accuracy, ensure regulatory compliance, and manage pharmacy spend. Based in New York City, Truveris is funded by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. For more information, visit truveris.com.

About Canaan Partners

Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $3.4 billion under management and over 150 exits to date, Canaan has funded some of the world’s leading technology companies including PrimeSense, Skybox Imaging and Virsto as well as healthcare stars like Labrys Biologics, Chimerix and Advanced BioHealing. Current investments include Kabam, Lending Club, and Zoosk for technology companies and Civitas Therapeutics, CytomX and DICOM Grid for healthcare. For more information visit www.canaan.com.

Other Investors

For more information on other investors visit:

www.nlvpartners.com – Series B lead
www.tribecavp.com
– Series A lead
www.navfund.com
www.firstround.com

SOURCE Truveris

RELATED LINKS

http://truveris.com

PR Newswire

0 notes &

TruNews: June 2014

Don’t overlook the value of claims auditing

Regular audits of pharmacy and medical claims can correct instances of duplicate billing, incorrect or missing discounts and rebates, mistakes in member eligibility, plan setup mistakes, and other problems. Audits also give plan sponsors the necessary information to revise contracts with TPAs and PBMs, leading to savings on top of possible recovery findings from the audit. 

Link to Article: Employee Benefit News

    

Allergan spurns Valeant again, but shareholders may have other ideas

Allergan, the manufacturer of Botox, has rejected Valeant’s increased bid for a second time. While Allergan’s board was unanimous in rejecting the bid, Valeant intends to go to shareholders with its latest $53 billion total offer.  

Link to Article: FiercePharma

    

Humana Pharmacy Benefit Unit Sale Could Fetch up to $7B

Humana is considering selling its pharmacy benefit management unit, which analysts expect could bring in $3.5-7.1B. Humana recently signed a distribution agreement with Wal-Mart for low-cost pharmacy access and could gain the ability to focus on other lines of business by selling the unit; perhaps to another PBM like CVS Caremark, Express Scripts, or Catamaran. 

Link to Article: Yahoo! Finance

    
Senate confirms Sylvia Matthews Burwell as new secretary of HHS

Sylvia Matthews Burwell, the White House’s budget director, has been confirmed as the Secretary of the Department of Health and Human Services. Burwell will oversee the 11 agencies comprising HHS, including NIH, CDC, FDA, and CMS. 

Link to Article: The Washington Post

Related Article: 4 million may pay PPACA penalty

    

Brokers on Record: What’s in a Name?

According to a recent report on benefit brokers, the title ‘Advisor’ is seeing an uptick in usage. ‘Agent,’ ‘Broker,’ and ‘Consultant’ rank highly as well. 

Link to Article: BenefitsPro

  

New Federal Guidelines on HIV Prevention Drug Could Add $ Billions to Drug Spending

In new clinical guidelines for providers published May 14, the U.S. Public Health Service recommends considering prescribing Gilead’s HIV drug Truvada for patients who are at high risk of contracting HIV but are currently HIV-negative. A key question in the feasibility of such an HIV prevention strategy is whether payers can sustain the price of Truvada: $13,000. 

Link to Article: RxObserver.com

     

Merck & Co to buy Idenix to boost hepatitis C drugs portfolio

Merck (MRK.N) announced its plan to purchase Idenix Pharmaceuticals Inc. (IDIX.O) for $3.85 billion to create synergies in producing hepatitis C treatments. Merck, paying $24.50 per share, aims to create a triple therapy ‘cure’ that would rival Gilead’s Sovaldi and cure all types of hepatitis C within 4-6 weeks. 

Link to Article: Reuters

                                                 ###

Read more …

0 notes &

TruNews: April 2014

CVS Caremark Reports Traditional Drug Trend Increased by
Just 0.8 Percent in 2013 While Overall Prescription Drug Trend is Up 3.8 Percent

In its annual Insights report, CVS Caremark reports that overall prescription drug trend is up 3.8% in 2013, compared to 0.1% in 2012. Driving the growth were price inflation for brand, specialty, and generic drugs and higher utilization as members filled more scripts. 

Link to Article: PR Newswire

Related: Prices Soaring for Specialty Drugs, Researchers Find | Express Scripts Releases Annual Drug Trend Report, Raises Pressure on Gilead for Drug Price

Walgreen pressured to move headquarters to Europe

Pressure is mounting for Walgreen Co., the U.S.’s largest pharmacy chain, to relocate its headquarters to Europe. Walgreen owns nearly half of Swiss-based drugstore company Alliance Boots, whose executives are advising moving Walgreen’s headquarters for tax purposes. 

Link to Article: Chicago Tribune    

     

Truveris VP Kristin Begley, Pharm.D., is Honored by Samford University

Congratulations to Truveris VP Kristin Begley, Pharm.D., honored by Samford University for her contributions to the pharmacy benefit world. The Centennial of Coeducation initiative recognized women every day in March for their achievements. 

Link to Article: Samford University

    

CVS Caremark Awarded Integrated, 3-Year Blue Cross and Blue Shield Federal Employee Program (FEP) Contract

CVS Caremark was awarded a three-year contract to provide pharmacy benefit services to the Federal Employee Program (FEP). More than 5 million beneficiaries are in the FEP. 

Link to Article: PR Newswire

           

Bill seeks price transparency from PBMs

Missouri state Senator David Sater has introduced a bill to require PBMs to disclose to network pharmacies more information about their business practices. Pricing data and maximum allowable cost (MAC) lists that reveal how much PBMs reimburse pharmacies and clients would be part of the information to be shared. 

Link to Article: St. Louis Business Journal

Related: Pharmacy legislation passes Ohio Senate | Experts to meet on impact of pharmaceutical drug bill on FL state workers insurance

7.5M Signed Up in Health Insurance Exchanges

7.5 million people had signed up for health insurance from the exchanges by April 10. Questions remain about how many of these people were previously uninsured, and not everyone who signs up pays the premium, meaning that the final enrollment number is expected to be lower.  

Link to Article: Politico

Related: What Happens Next on the Health Law? | Budget Chief Is Obama’s Choice as New Health Secretary | How healthy are the newly insured in the exchanges?

                                                  ###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 800.430.1430
www.truveris.com

0 notes &

TruNews: March 2014

Florida Senate Looks At Pharmacy Audits

A Florida Senate committee approved proposal SB 702 that would further restrict audits of pharmacies. Sen. Aaron Bean (R-Fernandina Beach) is sponsoring the bill, which aims to establish rights for pharmacies like receiving adequate notice before audits conducted by PBMs. 

Link to Article: The Ledger

      

Do drug benefit managers reduce health costs?

Legislation in 14 states is aiming to require more pricing disclosure by PBMs. The state efforts continue the goal of the HHS rule that took effect last year, which requires PBMs to inform the government of rebates and discounts received from drug manufacturers as PBMs process Medicare benefits. 

Link to Article: USA Today

     

Association: Nearly 600 Oklahoma pharmacies could go out of business soon

According to the Oklahoma Pharmacists Association (OPhA), nearly 600 state pharmacies may go out of business because they are forced into blind contracts with pharmacy benefit managers (PBMs) in which the pharmacies lose money. Oklahoma Senator Rob Standridge, a pharmacist, and Rep. David Derby co-authored House Bill 2100 that would aims to regulate PBMs and make actual drug costs more transparent to pharmacies. 

Link to Article: Kentucky NewsChannel 4

Obama Gives Health Plans Added Two-Year Reprieve

Federal officials are allowing insurance companies to continue selling some plans that do not meet some of the ACA’s standards until 2016. This marks the second delay of the law’s more stringent requirements. 

Link to Article: WSJ

Related: How Health-Insurance Subsidies Are Calculated | Insurers May Get Cost Break Thanks to Rocky ACA Rollout

           

Medicare drug changes put on hold after criticism

The Obama administration has canceled plans to overhaul the Medicare Part D program after substantial outcry from patient advocacy groups, lawmakers, and the industry. The main concern was that the overhaul would prevent seniors from accessing particular medications and plans. 

Link to Article: Politico

                                                 ###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 800.430.1430
www.truveris.com

0 notes &

TruNews: February 2014

White House delays health insurance mandate for medium-sized employers until 2016

The Obama administration is delaying the employer mandate for employers with 50 to 99 full-time workers until 2016. Originally set for 2014, then delayed until 2015, this deadline imposes a change for medium-sized employers, which had not previously offered insurance.

Link to Article: Washington Post

      image

Truveris Hires Walgreens, Apple Vet to Head Up Sales for Its Central Region

Truveris on Tuesday named Anthony Barrett VP sales, central region. During his Walgreens tenure, he served as SVP Walgreens Health Initiatives, leading a team developing breakthrough industry solutions and fully transparent contracting for rebates and networks. Prior to Walgreens, Anthony spent 17 years with Apple in enterprise divisional leadership roles, managing sales and business development teams. 

Link to Article: Drug Store News

image

     image

Top 10 Issues Roiling Healthcare in 2014

From a PwC analysis of polling data from healthcare industry experts, top 10 issues for 2014 touch on VC funding in healthcare, private exchanges, price transparency, and technology. Increasingly, consumers and employers have requested price transparency and valued choice. 

Link to Article: Healthcare Payer News

  image

Actavis Agrees to Buy Forest Labs for $25 Billion

image

Actavis PLC has announced it will acquire drug manufacturer Forest Laboratories for around $25 billion. Forest, based in New York, will enable Actavis, headquartered in Dublin, to address the Americam health care evolution in which hospitals, doctors, and health insurance companies are forming organizations that negotiate directly to purchase prescription drugs. 

Link to Article: WSJ

      image

At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Sovaldi, Gilead’s breakthrough new drug for Hepatitis C, costs $84,000. Express Scripts, Catamaran, CVS, and Aetna are among those pushing back against the high cost of the drug. 

Link to Article: Bloomberg

    image

State, Local Governments Spending More on Health Than Ever

For state and local governments, healthcare costs are growing faster than the national average, presenting competition for other services. State and local governments are spending about one-third of budgets on healthcare, a higher level than any time during the 27 years of such records.

Link to Article: Healthcare Payer News

image

CVS Earnings Rise on Growth in Drug Benefit Business 

CVS Caremark’s fourth-quarter earnings rose 12% on sales growth at its PBM and retail drugstore business. After announcing its end to selling cigarettes and tobacco products, CVS Caremark is also moving toward providing basic health services and forming a joint venture with Cardinal Health Inc. to source generic drugs. 

 Link to Article: WSJ

image

###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 800.430.1430
www.truveris.com

0 notes &

Truveris Names Anthony Barrett, Former Walgreens and Apple Executive, as VP of Sales of Central Region

image

NEW YORK – Truveris, Inc. is pleased to announce that Anthony J. Barrett has joined the company as Vice President of Sales, Central Region.

 Mr. Barrett joins Truveris with over 33 years of achieving growth and leading strategic business development, sales, and clinical teams.  Experienced in healthcare and IT, Mr. Barrett worked at Healthways, Prime Therapeutics, Walgreens, Apple, and Xerox.  During his Walgreens tenure he served as SVP of Walgreens Health Initiatives (PBM), leading a team developing breakthrough industry solutions and fully-transparent contracting for rebates and networks.

 Prior to Walgreens, Anthony spent 17 years with Apple in enterprise divisional leadership roles, managing sales and business development teams.  With Apple leading the global transition from analog to digital communications solutions, Anthony’s team created new channels of advocacy with partners that allowed Apple to scale rapidly.

 Mr. Barrett stated, “I’m excited to join Truveris because we share a common passion around transparency and simplifying pharmacy benefit complexities with technology.  After 17 years at Apple and 7 years at Walgreens in leadership roles, I know great innovation when I see it.  Truveris’ domain expertise combined with its SaaS technology is truly without equal.”

 Truveris CEO Bryan Birch stated, “Anthony’s combined experience in the technology and pharmacy industries is a perfect fit for Truveris.  Lazard has recognized us in their 2013 What’s Next: It’s Private report as one of only two companies to watch in the Managed Care and Health Care IT industries.  Anthony’s position at Truveris will help expand our capabilities and accelerate our product distribution.”

At Truveris, Anthony will apply a similar channel strategy to partner with brokers, TPAs, and consultants as he did at Apple; empowering advisers to deliver new and differentiated services to their clients.

About Truveris: 

Truveris, Inc. is the nation’s leading pharmacy benefit analytics company, reducing the cost of prescription drugs for payers like corporations, unions, health insurance companies, and governments.  Truveris analyzes hundreds of millions of claims annually through SaaS products including: TruBid, an automated RFP platform for selecting pharmacy benefit manager (PBM) plans; TruGuard, a scalable claims processing engine that readjudicates 100% of prescription drug claims; and TruReport, an analytics platform for health insurance companies.

Follow Truveris on Twitter or Facebook.

Press release: 

MarketWatch

Media Inquiries:

Stephanie Louis

Truveris

slouis@truveris.com

800.430.1430

0 notes &

TruNews: January 2014

CVS Caremark Completes $2.1B acquisition of Coram

CVS Caremark Corp. acquired Coram LLC for $2.1 billion, expecting the drug infusion company to help adjusted earnings next year by 3 to 5 cents. Coram, based in Denver, specializes on medications and food administered through tubes or veins that treat patients with rheumatoid arthritis, nutritional deficiencies, and immune deficiencies. 

Link to Article: Daily Herald Business Ledger

image

U.S. Health Spending Rising Modestly, Report Finds

A CMS analysis reports that health care spending in 2012 rose 3.7%, to $2.8 trillion; in the fourth consecutive year of modest spending growth between 3.6% and 3.8%. The author, Anne Martin, pointed to the lagged impact of the economic recession, slower growth in prescription drug prices, and increased sales of low-cost generics as influences in the stability since 2009. 

Link to Article: HealthDay 

     image

Alliant Insurance Buys Benefit Brokerage Sagewell

Alliant Insurance Services, based in Newport Beach, CA, has acquired Pittsburgh-based Sagewell Partners. David Osterhaus, CEO of Sagewell, will serve as executive vice president and managing director of Alliant. 

Link to Article: Business Insurance     

image

     image

UPMC Still Has Some Prescription Troubles

image

Starting at the beginning of 2014, a glitch has prevented an undisclosed amount of information in the University of Pittsburgh Medical Center (UPMC) Health Plan’s customer databases from being properly shared with Express Scripts, the PBM processing UPMC’s prescription claims. According to UPMC, the problem lies in Express Script’s new processing software and resulting delays in migrating policyholder data. 

Link to Article: Pittsburgh Post-Gazette

image

Medicare Advantage Enrollment Tops 15 Million

In December 2013, aggregated enrollment in Medicare Advantage plans reached 15.1 million, up almost 1.3 million members from December 2012. The report by Mark Farrah Associates, based on CMS enrollment data, pointed to October as the month in which membership exceeded 15 million, and noted Georgia, Texas, and Kentucky each gained more than 50,000 members. 

Link to Article: BenefitsPro   

image

Look Out for Herd Mentality In Pharma

R&D pipelines, while experiencing a boost in 2012 as U.S. regulators approved 39 drugs, may be hard to pinpoint in terms of strategic allocation of funds. There has been declining research in areas such as the central nervous system diseases, due to low success rates in late-stage trials; some accounts of a focus on oncology and inflammation R&D disproportionate to projected revenue; and other arguments suggesting depression and schizophrenia along may comprise a substantial market.

Link to Article: Wall Street Journal

image

Express Scripts Names Cathy R. Smith Chief Financial Officer

As of February 10, 2014; Cathy R. Smith will be the Executive Vice President and Chief Financial Officer of Express Scripts Holding Company. Ms. Smith previously was executive vice president of strategy and CFO for Walmart International. 

Link to Article: PR Newswire

image

###

Truveris  |  Trust but Verify
475 Park Avenue South | Suite 2950 | New York, NY 10016
Phone: 800.430.1430 | Fax: 800.430.1430
www.truveris.com